Assessment of commercial SARS-CoV-2 antibody assays, Jamaica
Background: The performance of the Roche Elecsys® Anti-SARS-CoV-2, Abbott Architect SARS-CoV-2 IgM, Abbott Architect SARS-CoV-2 IgG, Euroimmun SARS-CoV-2 IgA, Euroimmun SARS-CoV-2 IgG ELISA, and Trillium IgG/IgM rapid assays was evaluated in Jamaica. Methods: Diagnostic sensitivities of the assays w...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-04-01
|
| Series: | International Journal of Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971221001454 |
| _version_ | 1818827668493172736 |
|---|---|
| author | Tiffany R. Butterfield Alrica Bruce-Mowatt Yakima Z.R. Phillips Nicole Brown Keisha Francis Jabari Brown Jerome P. Walker Niel A.L. McKnight Kelvin Ehikhametalor Devon K. Taylor Carl A. Bruce Donovan McGrowder Gilian Wharfe Simone L. Sandiford Tamara K. Thompson Joshua J. Anzinger |
| author_facet | Tiffany R. Butterfield Alrica Bruce-Mowatt Yakima Z.R. Phillips Nicole Brown Keisha Francis Jabari Brown Jerome P. Walker Niel A.L. McKnight Kelvin Ehikhametalor Devon K. Taylor Carl A. Bruce Donovan McGrowder Gilian Wharfe Simone L. Sandiford Tamara K. Thompson Joshua J. Anzinger |
| author_sort | Tiffany R. Butterfield |
| collection | DOAJ |
| description | Background: The performance of the Roche Elecsys® Anti-SARS-CoV-2, Abbott Architect SARS-CoV-2 IgM, Abbott Architect SARS-CoV-2 IgG, Euroimmun SARS-CoV-2 IgA, Euroimmun SARS-CoV-2 IgG ELISA, and Trillium IgG/IgM rapid assays was evaluated in Jamaica. Methods: Diagnostic sensitivities of the assays were assessed by testing serum samples from SARS-CoV-2 PCR-confirmed persons and diagnostic specificity was assessed by testing serum samples collected during 2018–2019 from healthy persons and from persons with antibodies to a wide range of viral infections. Results: Serum samples collected ≥14 days after onset of symptoms, or an initial SARS-CoV-2 RT-PCR positive test for asymptomatics, showed diagnostic sensitivities ranging from 67.9 to 75.0% when including all possible disease severities and increased to 90.0–95.0% when examining those with moderate to critical disease. Grouping moderate to critical disease showed a significant association with a SARS-CoV-2 antibody positive result for all assays. Diagnostic specificity ranged from 96.7 to 100.0%. For all assays examined, SARS-CoV-2 real-time PCR cycle threshold (Ct) values of the initial nasopharyngeal swab sample testing positive were significantly different for samples testing antibody positive versus negative. Conclusions: These data from a predominantly African descent Caribbean population show comparable diagnostic sensitivities and specificities for all testing platforms assessed and limited utility of these tests for persons with asymptomatic and mild infections. |
| first_indexed | 2024-12-19T00:47:13Z |
| format | Article |
| id | doaj.art-6845cf11072c4856b2ab38ce7c4a4eb3 |
| institution | Directory Open Access Journal |
| issn | 1201-9712 |
| language | English |
| last_indexed | 2024-12-19T00:47:13Z |
| publishDate | 2021-04-01 |
| publisher | Elsevier |
| record_format | Article |
| series | International Journal of Infectious Diseases |
| spelling | doaj.art-6845cf11072c4856b2ab38ce7c4a4eb32022-12-21T20:44:14ZengElsevierInternational Journal of Infectious Diseases1201-97122021-04-01105333336Assessment of commercial SARS-CoV-2 antibody assays, JamaicaTiffany R. Butterfield0Alrica Bruce-Mowatt1Yakima Z.R. Phillips2Nicole Brown3Keisha Francis4Jabari Brown5Jerome P. Walker6Niel A.L. McKnight7Kelvin Ehikhametalor8Devon K. Taylor9Carl A. Bruce10Donovan McGrowder11Gilian Wharfe12Simone L. Sandiford13Tamara K. Thompson14Joshua J. Anzinger15The University of the West Indies, Department of Microbiology, Kingston, JamaicaThe University of the West Indies, Department of Microbiology, Kingston, JamaicaThe University of the West Indies, Department of Microbiology, Kingston, JamaicaThe University of the West Indies, Department of Microbiology, Kingston, JamaicaThe University of the West Indies, Department of Microbiology, Kingston, JamaicaThe University of the West Indies, Department of Pathology, Kingston, JamaicaThe University of the West Indies, Department of Microbiology, Kingston, JamaicaThe University of the West Indies, Department of Microbiology, Kingston, JamaicaThe University of the West Indies, Department of Anaesthesia and Intensive Care, Kingston, JamaicaAstraZeneca, Department of Oncology Research, Gaithersburg, MD, United StatesThe University of the West Indies, Department of Surgery, Kingston, JamaicaThe University of the West Indies, Department of Pathology, Kingston, JamaicaThe University of the West Indies, Department of Pathology, Kingston, JamaicaThe University of the West Indies, Department of Basic Medical Sciences, Kingston, JamaicaThe University of the West Indies, Department of Medicine, Kingston, JamaicaThe University of the West Indies, Department of Microbiology, Kingston, Jamaica; Global Virus Network, Baltimore, MD, United States; Corresponding author.Background: The performance of the Roche Elecsys® Anti-SARS-CoV-2, Abbott Architect SARS-CoV-2 IgM, Abbott Architect SARS-CoV-2 IgG, Euroimmun SARS-CoV-2 IgA, Euroimmun SARS-CoV-2 IgG ELISA, and Trillium IgG/IgM rapid assays was evaluated in Jamaica. Methods: Diagnostic sensitivities of the assays were assessed by testing serum samples from SARS-CoV-2 PCR-confirmed persons and diagnostic specificity was assessed by testing serum samples collected during 2018–2019 from healthy persons and from persons with antibodies to a wide range of viral infections. Results: Serum samples collected ≥14 days after onset of symptoms, or an initial SARS-CoV-2 RT-PCR positive test for asymptomatics, showed diagnostic sensitivities ranging from 67.9 to 75.0% when including all possible disease severities and increased to 90.0–95.0% when examining those with moderate to critical disease. Grouping moderate to critical disease showed a significant association with a SARS-CoV-2 antibody positive result for all assays. Diagnostic specificity ranged from 96.7 to 100.0%. For all assays examined, SARS-CoV-2 real-time PCR cycle threshold (Ct) values of the initial nasopharyngeal swab sample testing positive were significantly different for samples testing antibody positive versus negative. Conclusions: These data from a predominantly African descent Caribbean population show comparable diagnostic sensitivities and specificities for all testing platforms assessed and limited utility of these tests for persons with asymptomatic and mild infections.http://www.sciencedirect.com/science/article/pii/S1201971221001454COVID-19SARS-CoV-2AntibodySerologyCaribbeanJamaica |
| spellingShingle | Tiffany R. Butterfield Alrica Bruce-Mowatt Yakima Z.R. Phillips Nicole Brown Keisha Francis Jabari Brown Jerome P. Walker Niel A.L. McKnight Kelvin Ehikhametalor Devon K. Taylor Carl A. Bruce Donovan McGrowder Gilian Wharfe Simone L. Sandiford Tamara K. Thompson Joshua J. Anzinger Assessment of commercial SARS-CoV-2 antibody assays, Jamaica International Journal of Infectious Diseases COVID-19 SARS-CoV-2 Antibody Serology Caribbean Jamaica |
| title | Assessment of commercial SARS-CoV-2 antibody assays, Jamaica |
| title_full | Assessment of commercial SARS-CoV-2 antibody assays, Jamaica |
| title_fullStr | Assessment of commercial SARS-CoV-2 antibody assays, Jamaica |
| title_full_unstemmed | Assessment of commercial SARS-CoV-2 antibody assays, Jamaica |
| title_short | Assessment of commercial SARS-CoV-2 antibody assays, Jamaica |
| title_sort | assessment of commercial sars cov 2 antibody assays jamaica |
| topic | COVID-19 SARS-CoV-2 Antibody Serology Caribbean Jamaica |
| url | http://www.sciencedirect.com/science/article/pii/S1201971221001454 |
| work_keys_str_mv | AT tiffanyrbutterfield assessmentofcommercialsarscov2antibodyassaysjamaica AT alricabrucemowatt assessmentofcommercialsarscov2antibodyassaysjamaica AT yakimazrphillips assessmentofcommercialsarscov2antibodyassaysjamaica AT nicolebrown assessmentofcommercialsarscov2antibodyassaysjamaica AT keishafrancis assessmentofcommercialsarscov2antibodyassaysjamaica AT jabaribrown assessmentofcommercialsarscov2antibodyassaysjamaica AT jeromepwalker assessmentofcommercialsarscov2antibodyassaysjamaica AT nielalmcknight assessmentofcommercialsarscov2antibodyassaysjamaica AT kelvinehikhametalor assessmentofcommercialsarscov2antibodyassaysjamaica AT devonktaylor assessmentofcommercialsarscov2antibodyassaysjamaica AT carlabruce assessmentofcommercialsarscov2antibodyassaysjamaica AT donovanmcgrowder assessmentofcommercialsarscov2antibodyassaysjamaica AT gilianwharfe assessmentofcommercialsarscov2antibodyassaysjamaica AT simonelsandiford assessmentofcommercialsarscov2antibodyassaysjamaica AT tamarakthompson assessmentofcommercialsarscov2antibodyassaysjamaica AT joshuajanzinger assessmentofcommercialsarscov2antibodyassaysjamaica |